Science Applications International Corporation (SAIC) (NYSE:SAI - News) announced today the appointment of Dr. David Heimbrook as chief executive officer of SAIC-Frederick, Inc., a wholly owned subsidiary of SAIC, effective May 31. Heimbrook will succeed Dr. Larry Arthur, who has served as CEO since 2000 and will remain with SAIC-Frederick as chief scientist.
SAIC-Frederick provides operations and technical support to the National Cancer Institute's (NCI's) Federally Funded Research and Development Center (FFRDC) in Frederick, Md. The FFRDC is one of only 38 national laboratories in the United States and the only one solely dedicated to cancer and HIV/AIDS research. The FFRDC strives to develop new technologies and translate scientific discoveries into novel agents for the prevention, diagnosis, and treatment of cancer and AIDS. SAIC has supported NCI-Frederick since 1995 and in 2008 was awarded a new 10-year contract by the U.S. Department of Health and Human Services to continue that work.
Heimbrook will be responsible for the comprehensive management and oversight of all scientific and business activities conducted on the contract. He will lead SAIC-Frederick's staff of approximately 2,000 scientific, technical, and support professionals who perform basic and applied research in cancer and AIDS, and maintain a full suite of advanced technologies in areas such as nanotechnology, genomics and biomedical imaging.
Heimbrook brings more than 20 years of experience and progressive responsibility in cancer research, translational research and organizational management. Prior to joining SAIC-Frederick, he was the global head of discovery for the Oncology Discovery and Translation Area of Hoffman-LaRoche, Inc. Leading three cancer research sites, Heimbrook was responsible for developing and implementing Roche's oncology research strategy, including personalized healthcare and partnering relationships, and transitioning compounds through clinical proof-of-concept to pivotal registration studies. Heimbrook previously held positions with Merck Research Laboratories and Smith Kline & French Laboratories.
Heimbrook earned his Ph.D. in molecular biophysics and biochemistry from Yale University, a master's degree in molecular biophysics and biochemistry from Yale University, and a bachelor's degree in chemistry from Duke University. He will report to Joe Craver, president of SAIC's Health, Energy and Civil Solutions Group.
"We are deeply appreciative of Larry Arthur's outstanding leadership over the past 11 years," said Craver. "Looking forward, we are confident Dave's extensive knowledge and experience in the national healthcare and scientific research community will be of tremendous benefit to the important work SAIC is providing for NCI's world-class research facility. He has an outstanding track record of managing research organizations, and I anticipate he will deliver exceptional service and leadership to NCI and to our employees."
SAIC is a FORTUNE 500® scientific, engineering, and technology applications company that uses its deep domain knowledge to solve problems of vital importance to the nation and the world, in national security, energy and the environment, critical infrastructure, and health. The company's approximately 43,000 employees serve customers in the U.S. Department of Defense, the intelligence community, the U.S. Department of Homeland Security, other U.S. Government civil agencies and selected commercial markets. Headquartered in McLean, Va., SAIC had annual revenues of $11.1 billion for its fiscal year ended January 31, 2011. For more information, visit www.saic.com. SAIC: From Science to Solutions®
Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in SAIC's Annual Report on Form 10-K for the period ended January 31, 2011, and other such filings that SAIC makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.